In a year where ADC deals have showed no signs of slowing, Solve has become the latest biotech to unlock an extra slice of capital.

Johnson & Johnson has signed a definitive agreement for the acquisition of Halda Therapeutics (Halda) in a deal valued at ...

Merus and Halozyme have signed a worldwide non-exclusive partnership and licence agreement for subcutaneous formulation of ...

A CHMP panel has recommended the high-dose version’s approval, countering an FDA rejection for the drug in recent months.

Medicxi will use the €500m kitty to continue supporting drug hunters and entrepreneurs in creating asset-focused ...

Komzifti now becomes the first once-daily targeted therapy for r/r AML, though it will have to fight Syndax’s Revuforj for ...

The “plausible mechanism pathway” will allow personalised drugs to reach the market sooner for patients with genetic diseases ...

The two drugmakers swiftly denied any affiliation with Mangoceuticals, who claimed it had partnered with them.

Eisai and Biogen have announced UK MHRA approval for Leqembi for intravenous (IV) maintenance dosing to treat early Alzheimer ...

MSD has now agreed two deals around the $10bn mark in 2025 as it looks to shore up its pipeline with Keytruda’s looming ...

The US Food and Drug Administration (FDA) has a new chief drug regulator, with industry veteran Dr Richard Pazdur taking the ...

BostonGene and Kyoto University have collaborated to advance precision drug development for oesophageal squamous cell ...